CSIMC Recommends NHI Price Listing for 15 APIs/20 Products

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story


Can Pharmas and Wholesalers Work to Dispel “Negative Primary Margins on Sales”?


Pharmaceuticals and Medical Devices Law:

The Column

What You Don’t Know About Communication Can Hurt You


Novartis Pharma Should Take Thorough Measures to Prevent Worker Involvement in IITs: Health Minister(Dec.22)
EFPIA Japan Chairman Calls for More Rewards for Innovation(Dec.22)
New “Compassionate Use” System to Be Introduced in FY2015; Will Apply to Industry-Sponsored Trials as well as IITs(Dec.22)
Orphan Designation to Be Expanded to Include Intractable Diseases Affecting More than 50,000 Patients(Dec.22)
Ono Licenses Exclusive Worldwide Rights for BTK Inhibitor to Gilead Excluding East and South East Asia(Dec.22)

Most Read

JPMA Will Work ...
Pharmacist Soci...
Drug Makers Pre...
JMA Chief Lauds...
Japan Tax Refor...

News Calendar